ReviewJournal of clinical medicine2023
Chondrosarcoma: A Clinical Review.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024.Frontiers in oncology · 2024Pooled it
- Recurrent Dedifferentiated Clival Chondrosarcoma Presenting 32 Years after Initial Treatment: A Case Report.Journal of neurological surgery reports · 2026Article
- [Resection of a chondrosarcoma of the first metacarpal and reconstruction using composite osteosynthesis : Case report and literature review].Unfallchirurgie (Heidelberg, Germany) · 2026Article
- High-Grade Chondrosarcoma Involving the Xiphoid Process and Lower Sternum-The Continuing Role of Extended Open Chest Wall Surgery in the Era of Minimally Invasive Thoracic Surgery: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.Cancer treatment reviews · 2026Review
- Identification of immunopeptides (pHLA) as candidate therapeutic targets in chondrosarcoma.Journal of bone oncology · 2026Article
- Review
- Impact of Surgical Margins in Chest Wall Chondrosarcomas: A CanSaRCC Study.Journal of surgical oncology · 2026Observational
- Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.Cancer immunology research · 2026Article
- Investigating possible predictors of malignant transformation of osteochondroma: a retrospective cohort study with an illustrative case report.Skeletal radiology · 2026Article
- Robot-Assisted "Postage-Stamp" Vertebrotomy for Spinal Tumor Resection: Case Report.Journal of clinical medicine · 2026Article
- Article
- YouTube as a Source of Patient Information for Malignant and Benign Primary Bone Tumors.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Isocitrate dehydrogenase mutations as potential tumour agnostic targets.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2026Article
- Guided Limited Maxillectomy and Staged Septal-Palatal Reconstruction for Low-Grade Chondrosarcoma of the Hard Palate: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Article
- Risk Factors, Clinical Manifestations, and Treatment Outcomes of Primary Bone Sarcomas.Saudi medical journal · 2026Article
- Actionable diagnostic delay in primary malignant bone tumors: a trigger-to-action framework for first-contact clinicians.Frontiers in oncology · 2026Review
- Targeting Grade-Specific Endoplasmic Reticulum Stress Vulnerabilities in Chondrosarcoma: Divergent Roles of Protein Kinase R-Like Endoplasmic Reticulum Kinase and Inositol-Requiring Enzyme 1α Signaling.Cancer communications (London, England) · 2026Article
- A radiology-based differential diagnostic model for pelvic chondrosarcoma using random forest algorithms.Frontiers in oncology · 2026Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondrosarcomas are a diverse group of malignant cartilaginous matrix-producing neoplasms. Conventional chondrosarcomas are a continuum of disease based on the biologic activity of the tumor. The tumors range from the relatively biologically benign low-grade tumors or intermediate atypical cartilaginous tumors (ACTs), to malignant, aggressive high-grade tumors. The clinical presentation, radiographic and pathologic findings, treatments and outcomes vary significantly based on the histologic grade of the tumor. Chondrosarcomas present a diagnostic dilemma, particularly in the differentiation between high- and intermediate-grade tumors and that of low-grade tumors from benign enchondromas. A multidisciplinary team at a tertiary sarcoma centre allows for optimal care of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.